Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645 · see citing works

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · see citing works

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · see citing works

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786 · see citing works

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · see citing works

Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer

Castro, E., Goh, C. L., Olmos, D., Saunders, E. J., Leongamornlert, D. A., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 854 · see citing works

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792 · see citing works

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration

Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694 · see citing works

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients

Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387 · see citing works

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

van Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 209 · see citing works

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Paller, C. J., Antonarakis, E. S., Beer, T. M., Borno, H. T., Carlo, M. I., George, D. J., Graff, J. N., Gupta, S., Heath, E. I., Higano, C. S., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.04.013 · Cited by 67 · see citing works

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

Sonpavde, G., Agarwal, N., Pond, G. R., Nagy, R. J., Nussenzveig, R. H., Hahn, A. W., Sartor, O. A., Gourdin, T. S., Nandagopal, L., Ledet, E. M., et al. (2019) · Cancer · doi:10.1002/cncr.31959 · Cited by 56 · see citing works

DNA repair defects in prostate cancer: impact for screening, prognostication and treatment

Warner, E. W., Yip, S., Chi, K. N., & Wyatt, A. W. (2018) · British Journal of Urology · doi:10.1111/bju.14576 · Cited by 42 · see citing works

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W. M., Alumkal, J. J., Beer, T. M., Beltran, H., George, D. J., Heath, E. I., Higano, C. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00060 · Cited by 30 · see citing works

Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN)

Galot, R., & Machiels, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101992 · Cited by 26 · see citing works

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer

Zhu, J., Tucker, M. D., Marin, D., Gupta, R. T., Healy, P. N., Humeniuk, M. S., Jarvis, C., Zhang, T., McNamara, M. A., George, D. J., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.06.015 · Cited by 24 · see citing works

Utilization of Tumor Genomics in Clinical Practice: An International Survey among ASCO Members

Barroso‐Sousa, R., Guo, H., Srivastava, P., James, T. A., Birch, W., Siu, L. L., Tew, W. P., & Tolaney, S. M. (2019) · Future Oncology · doi:10.2217/fon-2019-0010 · Cited by 20 · see citing works

Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

Higano, C. S., Sternberg, C. N., Fred Saad, C., TOMBAL, B. F., Miller, K., Kalinovský, J., Jiao, X., Tangirala, K., & Sartor, O. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.256 · Cited by 14 · see citing works

Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

George, D. J., Sternberg, C. N., Sartor, O. A., Fred Saad, C., TOMBAL, B. F., Miller, K., Kalinovský, J., Jiao, X., Tangirala, K., & Higano, C. S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.253 · Cited by 4 · see citing works

Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC).

Shore, N. D., Oliver, L., Shui, I. M., Gayle, A., Wong, O. Y., Kim, J., Payne, S., & Ghate, S. R. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.229 · Cited by 3 · see citing works

Real-World Homologous Recombination Repair Mutation Testing in Metastatic Castration-Resistant Prostate Cancer in the USA, Europe and Japan

Leith, A., Ribbands, A., Kim, J., Last, M., Barlow, S. G., Yang, L., & Ghate, S. R. (2022) · Future Oncology · doi:10.2217/fon-2021-1113 · Cited by 33 · see citing works

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32 · see citing works

Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer

Schostak, M., Bradbury, A. R., Briganti, A., de Castro, D. G., Gomella, L. G., Mateo, J., Penault-Llorca, F. M., Stenzinger, A., Wyatt, A. W., & Bjartell, A. S. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.08.004 · Cited by 25 · see citing works

Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial

Shore, N. D., Gazi, M., Pieczonka, C. M., Heron, S. P., Modh, R. A., Cahn, D. J., Belkoff, L. H., Berger, A., Mazzarella, B. C., VEYS, J. A., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.07.008 · Cited by 25 · see citing works

Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases

Shui, I. M., Burcu, M., Shao, C., Chen, C., Liao, C.-Y., Jiang, S., Cristescu, R., & Parikh, R. B. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00764-1 · Cited by 24 · see citing works

Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

Barata, P. C., Assayag, J., Li, B. C., Siu, G., & Niyazov, A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0851 · Cited by 20 · see citing works

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer

Kimura, H. M., Mizuno, K., Shiota, M., Narita, S., Terada, N., Fujimoto, N., Ogura, K., Hatano, S., Iwasaki, Y., Hakozaki, N., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01915-2 · Cited by 20 · see citing works

Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors

Wong, W. B., Anina, D., Lin, C.-W., & Adams, D. V. (2022) · Personalized Medicine · doi:10.2217/pme-2021-0174 · Cited by 12 · see citing works

Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer

Moretz, C., Byfield, S. D., Hatchell, K. E., Dalton, J. C., Onglao, P. N., Hang, L., Hansen, P., Radford, C. L., Nielsen, S. M., Heald, B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.38167 · Cited by 12 · see citing works

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Shore, N. D., Nielsen, S. M., Esplin, E. D., Antonarakis, E. S., Barata, P. C., Beer, T. M., Beltran, H., Bryce, A. H., Cookson, M. S., Crawford, E. D., et al. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00626 · Cited by 11 · see citing works

Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation

Fred Saad, C., Armstrong, A. J., Shore, N. D., George, D. J., Oya, M., Sugimoto, M., McKay, R. R., Hussain, M., & Clarke, N. W. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01146-4 · Cited by 10 · see citing works

Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer

Hung, A., Candelieri-Surette, D., Li, Y., Alba, P. R., Robison, B., Agiri, F. Y., Perez, C., Lee, K., Maxwell, K. N., Li, W., et al. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.03.001 · Cited by 9 · see citing works

A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China

Gratzke, C., Aggarwal, H., Kim, J., Chaignaud, H., & Oskar, S. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.07.113 · Cited by 8 · see citing works

Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches

Kopp, R. M., Aláez‐Verson, C., Angel, M. O., Delgado, A., Velho, P. I., Manduley, A., Tejado-Gallegos, L. F., Rodríguez, Y., Vargas, C., & Barata, P. C. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00628 · Cited by 7 · see citing works

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer

Bilen, M. A., Burbage, S. C., Rossi, C., Khilfeh, I., Diaz, L., Wang, Y., Pilon, D., Brown, G. A., Shore, N. D., Lowentritt, B. H., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03270-z · Cited by 5 · see citing works

Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey

Bitting, R. L., McNair, C. M., Wyatt, A. W., Vandekerkhove, G. R., Choi, T., Leader, A. E., Blanding-Godbolt, J., Gross, L., Hamade, K., Halabi, S., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00821 · Cited by 5 · see citing works

Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race

Bilen, M. A., Khilfeh, I., Rossi, C., Muser, E., Morrison, L., Hilts, A., Diaz, L., Lefèbvre, P., Pilon, D., & George, D. J. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s468680 · Cited by 3 · see citing works

Genetics in prostate cancer: implications for clinical practice.

Szymaniak, B. M., Ross, A. E., & Morgans, A. K. (2021) · CiteSeer X (The Pennsylvania State University) · doi:10.1097/spc.0000000000000575 · Cited by 2 · see citing works

Current Practices in Genetic Testing for Prostate Cancer: The Indian Scenario

Bakshi, G., Rajappa, S. J., Joshi, A., Desai, C., Addla, S. K., Baxi, H. A., Talwar, V., Mohapatra, P. N., Shingla, S., & Kulkarni, U. (2024) · Indian Journal of Public Health · doi:10.4103/ijph.ijph_686_23 · Cited by 2 · see citing works

Genetic Testing for Prostate Cancer, Urothelial Cancer, and Kidney Cancer

Han, H. H., Kang, M., Byun, S., & Yun, S. J. (2023) · Journal of Urologic Oncology · doi:10.22465/juo.234600340017 · Cited by 2 · see citing works

The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants

Teppala, S., Scuffham, P., Edmunds, K., Roberts, M. J., Smith, D. P., Fairbairn, D. J., Horvath, L. G., & Tuffaha, H. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101463 · Cited by 1 · see citing works

Utilization of genetic evaluation in patients with kidney cancer who meet guidelines for genetic referral

Makarova, E., Bakhl, K., Demirsoy, Ş., Xu, K., Ryu, G. S., Raman, J. D., Baker, M. W., & Truong, H. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.06.009 · Cited by 1 · see citing works

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes

Autio, K. A., Kyriakopoulos, C. E., Palyca, P., Xiao, H., Emamekhoo, H., Danila, D. C., Jan, M., Catharine, V., Riedel, E., Devitt, M. E., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01580-1 · Cited by 1 · see citing works

Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives

Jain, R., Ribbands, A., Butcher, J., Barlow, S. G., Skilling, J., Stevens, A., & Pascoe, K. C. (2025) · Future Oncology · doi:10.1080/14796694.2025.2577337 · Cited by 1 · see citing works

Systemic Treatments of Castration-Resistant Prostate Cancer

Desai, A. N., Fleyshman, M., Lall, N., & Saraiya, B. (2026) · Urologic Clinics of North America · doi:10.1016/j.ucl.2026.02.013 · Cited by 1 · see citing works

Global Disparity in Access to Novel Therapeutics for Metastatic Prostate Cancer

Anton, A., & Tran, B. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00595 · Cited by 1 · see citing works

Pathogenic BRCA2 c.6341del gene variant in a patient with prostatic cancer from the North Ossetia

Bolieva, M. B., Brovkina, O., Ходырев, Д. С., Nikitin, A. G., Epkhiev, A. A., Михайловна, В. Л., & Gordiev, M. (2023) · Cancer Urology · doi:10.17650/1726-9776-2023-19-3-94-99

Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer

Candelieri-Surette, D., Hung, A., Agiri, F. Y., Hu, M., Hanchrow, E. E., Lee, K. M., Chang, N.-C. N., Yin, M., Shevach, J. W., Li, W., et al. (2025) · JCO Clinical Cancer Informatics · doi:10.1200/cci-24-00189

Assessing germline genetic testing patterns, awareness, and adherence to guidelines among lebanese prostate cancer patients

Seif, S., Najdi, T. A., Chebly, A., Bassil, M., Atme, N. B., Khnaisser, R., & Kattan, J. G. (2026) · BMC Urology · doi:10.1186/s12894-026-02300-4

A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles

Szymaniak, B. M., Morgans, A. K., & Shore, N. D. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01159-z

From genomic insights to public health impact: opportunities, challenges, and future directions in personalized disease prevention

Ayinde, M., Khairat, K., Dangana, A., Koshechkin, K., & Raheem, M. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20254068

Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program

Caramelo, B., García-Berbel, P., Carmen, S. D., Terán, A. K. C., Corrêa, L., Martinez-Villaseñor, L., Sotelo, M., Rojo, F., Gómez‐Román, J., Durán, I., et al. (2026) · Cancers · doi:10.3390/cancers18101614

Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer

Mahmud, S. A., Orr, L. D., Cline, M., Mirsalehi, A., Lisi, M., Ensley, L., Brisbin, L., & Paulson, R. S. (2026) · The Oncologist · doi:10.1093/oncolo/oyag243

Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States

George, D. J., Kariburyo-Yay, F., Aggarwal, H., Tepsick, J. G., Yu, R. S. H., Li, W., Orji, C., & Ghate, S. R. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.06.017

Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City

Rodríguez-Olivares, J. L., Pineda, M. M., Beas-Lozano, E. L., Seidman-Sorsby, A., Remolina-Bonilla, Y. A., Gamboa‐Domínguez, A., Weitzel, J. N., Barata, P., Chavarri-Guerra, Y., & Bourlon, M. T. (2026) · ONCOLOGY · doi:10.46883/2026.25921234

Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

Barata, P. C., Assayag, J., Li, B. C., Siu, G., & Niyazov, A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0851 · Cited by 20 · see citing works

1832P Centralized screening for homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A feasibility study from a multicenter Spanish cohort

Freire, J., Caramelo, B., Martinez, I. D., del Carmen, S., Azueta, A., García-Berbel, P., Diaz, P. D., Lavín, D. C., Orellana, M., Lencina, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.2780

Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives

Jain, R., Ribbands, A., Butcher, J., Barlow, S. G., Skilling, J., Stevens, A., & Pascoe, K. C. (2025) · Future Oncology · doi:10.1080/14796694.2025.2577337 · Cited by 1 · see citing works

Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States.

Leith, A., Ribbands, A., Last, M., Gayle, A., Payne, S., McCrea, C., Yang, L., Burgents, J. E., & Ghate, S. R. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.6_suppl.49 · Cited by 6 · see citing works

Gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024).

McKay, R. R., Li, W., Roose, J. P., Kerr, B. T., Karwa, S., Orji, C., Yeh, N., Cain, T., Yong, J. H. E., & Mukherjee, K. (2026) · Journal of Clinical Oncology · doi:10.1200/jco.2026.44.7_suppl.102